Methods, Apparatuses, and Systems for Creating a Patient-Specific Soft Bolus for Radiotherapy Treatment
US Patent US10835759B2, November 17, 2020
Methods, apparatuses, systems, and implementations for creating a patient-specific soft bolus for radiotherapy treatment are disclosed. 2D and/or 3D images of a desired radiotherapy treatment site may be acquired, such as the head, neck, skin, breast, anus, and/or vulva. A user may interact with one or more representations of the images via an interactive user interface such as a graphical user interface (GUI). The images may include target/avoidance structures and radiation beam arrangement. The user may interact with the images to create a visualization of a patient-specific bolus. The visualization and properties of the bolus may be modified as the user manipulates aspects of the image. Data corresponding to the bolus models may be used to create 3D printed negative molds of the bolus model using 3D printing technology. A soft patient-specific bolus may be cast using the 3D printed model.
Small Molecule Inhibitors of Src Tyrosine Kinase
PCT/US2020/038325, June 20, 2019
Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also disclosed herein are methods of using the compounds of Formula (I) in the treatment of certain diseases (e.g., cancer).
Quinazoline and Trisubtituted Benzene Derivatives from Isatoic Anhydride-8-amide and Derivatives Thereof
US Patent Application 62823362, March 25, 2019
The present disclosure provides derivatives of isatoic anhydride, methods of synthesizing said derivatives, and methods of synthesizing compounds using said derivatives of isatoic anhydride.
Universal Small Molecule Binding Assay for GTP-Competitive Inhibitors.
US Patent application 62181899, July 7, 2015.
The present invention relates generally to the field of molecular biology and drug screening. More particularly, it concerns methods of producing nucleoside di- and triphosphate-free GTPases and methods of screening modulators of GTPases.
RAS Inhibitors and Uses Thereof
PCT/US2014/026033, October 2, 2014
Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.
Detection of Irreversible Inhibitor Binding by Chemical Probes
US Patent application 62006622, June 2, 2014
The invention described here consists of chemical probes that are reactive with the target cysteine and go from being undetectable to detectable once that reaction occurs. To date we have used chemicals that give colorimetric (Elman’s reagent-5,5′-Dithiobis(2- nitrobenzoic acid)) and fluorescent (CPM-7-Diethylamino-3-(4-maleimidophenyl)-4- methylcoumarin) signals upon reacting with the target cysteine and a range of other similar compounds which exhibit a change in fluorescence upon reaction with free cysteines could be used in this assay (eg DACM-N-(7-Dimethylamino-4-Methylcoumarin-3-yl))Maleimide; N-(1- pyrene)maleimide; and Monobromobimane).